Clinical Protocol: A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma. Albert Einstein Center, Bronx, New York.
- 1 May 2000
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 11 (7), 1065-1082
- https://doi.org/10.1089/10430340050015374
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Recent Advances in the Care of the Patient with Malignant MelanomaAnnals of Surgery, 1997
- Do human cancers express sharedprotectiveantigens? or The necessity of remembrance of things pastSeminars in Immunology, 1996
- Expression of MHC Class II and B7–1 and B7–2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cellsTissue Antigens, 1996
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- Co‐expression of B7‐1 and ICAM‐1 on tumors is required for rejection and the establishment of a memory responseEuropean Journal of Immunology, 1995
- T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell ProfilesCritical Reviews in Immunology, 1995
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Preclinical studies, experimental therapeutics, and clinical management of advanced melanomaCurrent Opinion in Oncology, 1992
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988